Anti-CGRP compositions and use thereof

Patent metadata

Field	Value
Publication number	US-10066009-B2
Application number	US-201615257562-A
Country	US
Kind code	B2
Filing date	Sep 6, 2016
Priority date	May 20, 2011
Publication date	Sep 4, 2018
Grant date	Sep 4, 2018

Abstract

The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

First claim

What is claimed is:

1. A method of treatment comprising administering to a patient with a disease or condition associated with elevated CGRP a therapeutically effective amount of at least one anti-human CGRP antibody or fragment comprising a variable light chain comprising the complementarity-determining regions (CDRs, or hypervariable regions) of SEQ ID NO: 55; SEQ ID NO: 56; and SEQ ID NO: 57, and comprising a variable heavy chain comprising the complementarity-determining regions (CDRs, or hypervariable regions) of SEQ ID NO: 58; SEQ ID NO: 59; and SEQ ID NO: 60 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 53 or the heavy chain sequence of SEQ ID NO: 54.

2. The method of claim 1 wherein the anti-human CGRP antibody or antibody fragment contains an Fc region that has been modified to alter effector function, half-life, proteolysis, and/or glycosylation.

3. The method of claim 1 wherein the anti-human CGRP antibody or antibody fragment is a humanized, single chain or chimeric antibody.

4. The method of claim 1 wherein the disease is selected from migraine (with or without aura), weight loss, cancer or tumors, angiogenesis associated with cancer or tumor growth, angiogenesis associated with cancer or tumor survival, migraine, chronic migraine, frequent episodic migraines, or menstrual migraines hemiplegic migraines, cluster headaches, migrainous neuralgia, chronic headaches, tension headaches, general headaches, hot flushes, chronic paroxysomal hemicrania, secondary headaches due to an underlying structural problem in the head or neck, cranial neuralgia, sinus headaches (such as for example associated with sinusitis), allergy-induced headaches or migraines, pain, inflammatory pain, post-operative incision pain, complex regional pain syndrome, cancer pain, primary or metastatic bone cancer pain, fracture pain, osteoporotic fracture pain, pain resulting from burn, osteoporosis, gout joint pain, pain associated with sickle cell crises, and other nociceptic pain, as well as hepatocellular carcinoma, breast cancer, liver cirrhosis, neurogenic pain, neuropathic pain, nociceptic pain, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, fibromyalgia, menstrual pain, ovarialgia, reflex sympathetic dystrophy, neurogenic pain, osteoarthritis or rheumatoid arthritis pain, lower back pain, diabetic neuropathy, sciatica, or visceral pain associated with gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ileitis, ulcerative colitis, renal colic, dysmenorrhea, cystitis, menstrual period, labor, menopause, prostatitis, or pancreatitis or comprises overactive bladder; urinary incontinence; pain; chronic pain; neurogenic inflammation and inflammatory pain; neuropathic pain; eye pain; tooth pain; post-surgical pain, trauma related pain, diabetes; non-insulin dependent diabetes mellitus and other inflammatory autoimmune disorders, vascular disorders; inflammation; arthritis; bronchial hyperreactivity, asthma; shock; sepsis; opiate withdrawal syndrome: morphine tolerance; hot flashes in men and women; allergic dermatitis; psoriasis; encephalitis: brain trauma; epilepsy: neurodegenerative diseases; skin diseases including pruritis, neurogenic cutaneous redness, skin rosaceousness and erythema: inflammatory bowel disease, irritable bowel syndrome, cystitis; and dysmenorrhea.

5. The method of claim 4 , wherein the antibody or antibody fragment comprises a V H polypeptide sequence of SEQ ID NO:53; and a V L polypeptide sequence of SEQ ID NO:51.

6. The method of claim 1 , wherein the treatment further includes the administration of another therapeutic agent or regimen selected from anti-histamines, anti-inflammatory agents, analgesics or antibiotics.

7. The method of claim 1 wherein the antibody comprises a V H polypeptide comprising the sequence of SEQ ID NO:53; and a V L polypeptide comprising the sequence of SEQ ID NO:51.

8. The method of claim 7 which is used to treat or prevent headache.

9. The method of claim 8 wherein said headache is associated with a condition selected from migraine with aura, migraine without aura, chronic migraine, frequent episodic migraine, menstrual migraine, hemiplegic migraine, cluster headache, migrainous neuralgia, chronic headache, tension headache, general headache, hot flush, chronic paroxysmal hemicrania, secondary headache due to an underlying structural problem in the head or neck, cranial neuralgia, sinus headache, and allergy-induced headache or migraine.

10. The method of claim 9 wherein the antibody or antibody fragment is used to treat or prevent chronic migraine, or frequent episodic migraine.

11. The method of claim 7 which is used to treat or prevent migraine.

12. The method of claim 1 wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:54; and a light chain comprising the sequence of SEQ ID NO:52.

13. The method of claim 12 which is used to treat or prevent headache.

14. The method of claim 13 wherein said headache is associated with a condition selected from migraine with aura, migraine without aura, chronic migraine, frequent episodic migraine, menstrual migraine, hemiplegic migraine, cluster headache, migrainous neuralgia, chronic headache, tension headache, general headache, hot flush, chronic paroxysmal hemicrania, secondary headache due to an underlying structural problem in the head or neck, cranial neuralgia, sinus headache, and allergy-induced headache or migraine.

15. The method of claim 14 wherein the antibody or antibody fragment is used to treat or prevent chronic migraine, or frequent episodic migraine.

16. The method of claim 12 which is used to treat or prevent migraine.

17. The method of claim 1 which is used to treat or prevent headache.

18. The method of claim 17 wherein said headache is associated with a condition selected from migraine with aura, migraine without aura, chronic migraine, frequent episodic migraine, menstrual migraine, hemiplegic migraine, cluster headache, migrainous neuralgia, chronic headache, tension headache, general headache, hot flush, chronic paroxysmal hemicrania, secondary headache due to an underlying structural problem in the head or neck, cranial neuralgia, sinus headache, and allergy-induced headache or migraine.

19. The method of claim 18 wherein the antibody or antibody fragment is used to treat or prevent chronic migraine, or frequent episodic migraine.

20. The method of claim 1 is used to treat or prevent migraine.

21. A method of ameliorating or reducing symptoms of a disease or disorder associated with elevated CGRP comprising administering to an individual in need thereof a therapeutically effective amount of a CGRP antibody or antibody fragment comprising a variable light (V L ) chain comprising the complementarity-determining regions (CDRs, or hypervariable regions) of SEQ ID NO: 55; SEQ ID NO: 56; and SEQ ID NO: 57, and comprising a variable heavy (V H ) chain comprising the complementarity-determining regions (CDRs, or hypervariable regions) of SEQ ID NO: 58; SEQ ID NO: 59; and SEQ ID NO: 60 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 53 or the heavy chain sequence of SEQ ID NO: 54.

22. The method of claim 21 , wherein said disease or disorder is selected from migraine (with or without aura), weight loss,

Assignees

• Alderbio Holdings Llc

Inventors

• Kovacevich Brian Robert
• Garcia-Martinez Leon F
• Anderson Katie Olson
• Dutzar Benjamin H
• Billgren Jens J
• Latham John A
• Mitchell Danielle M
• Mcneill Patricia Dianne
• Janson Nicole M
• Loomis Maria-Cristina

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07K16/26 Primary

  against hormones {; against hormone releasing or inhibiting factors} · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title